Tuesday, February 22, 2000
European biotech companies quoted on NASDAQ appear to be missing
out on the wild investor enthusiasm in the U.S. With the BioCentury 100 index
rising 166 percent since Oct. 15, only Genset (NM:Genset; GENXY) and Qiagen
(NMarkt:QIA; QGENF) seem to be keeping pace with the NASDAQ crowd. British companies
on NASDAQ have turned in performances that are more in line with the 84 percent
improvement in the BioCentury London Index over the same period.
The top performing European stock
on NASDAQ in the last five months is the French genomics play Genset, which
is up nearly 400 percent since Oct. 15, taking its market cap to r1.4
billion ($1.4 billion).